Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Operating Expenses (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Operating Expenses for 14 consecutive years, with $5.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses rose 5.21% year-over-year to $5.0 million, compared with a TTM value of $23.0 million through Sep 2025, up 20.89%, and an annual FY2024 reading of $20.7 million, up 19.96% over the prior year.
  • Operating Expenses was $5.0 million for Q3 2025 at Sunshine Biopharma, down from $6.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $24.9 million in Q4 2022 and bottomed at $397842.0 in Q4 2021.
  • Average Operating Expenses over 5 years is $4.5 million, with a median of $4.1 million recorded in 2023.
  • The sharpest move saw Operating Expenses soared 6161.52% in 2022, then plummeted 81.63% in 2023.
  • Year by year, Operating Expenses stood at $397842.0 in 2021, then surged by 6161.52% to $24.9 million in 2022, then tumbled by 81.63% to $4.6 million in 2023, then skyrocketed by 36.02% to $6.2 million in 2024, then decreased by 19.82% to $5.0 million in 2025.
  • Business Quant data shows Operating Expenses for SBFM at $5.0 million in Q3 2025, $6.6 million in Q2 2025, and $5.2 million in Q1 2025.